LONZA GROUP AG |
Verzögert
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
| 293.9 EUR | +1.48% |
|
-.--% | -.--% |
| 12.06. | Aktien Schweiz von US-Daten beflügelt | DJ |
| 04.06. | Aktien Schweiz unverändert - Defensive Schwergewichte stützen | DJ |
Kurzporträt
- bio-pharmazeutische Produkte (55,4%): exklusive Synthesen, mikrobiologische Fermentierungsprodukte, Zellkulturen von Säugetieren, usw. ;
- Kapseln und Dosierungslösungen für Biopharmazeutika, Arzneimittel und Ernährungsprodukte an. (17,3%). Darüber hinaus bietet die Gruppe Nahrungsbestandteile;
- niedermolekulare Wirkstoffe (13,4%);
- Technologien und Plattformen zur Umsetzung der Herstellungsprozesse und der Produktion von Zell- und Gentherapien (10,4%);
- sonstige (3,5%).
Geographisch gesehen verteilt sich der Umsatz wie folgt: Schweiz (17,4%), Europa (31,7%), Vereinigte Staaten (31,8%), Nord- und Südamerika (3,2%), Japan (8,1%), Asien (7,5%) und sonstige (0,3%).
Mitarbeiterzahl: 18 000
Umsatz nach Geschäftsbereich
| CHF in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
Biologics
55,4
%
| 3 274 | 52,6 % | 3 719 | 55,4 % | +13.59% |
Capsules & Health Ingredients
17,3
%
| 1 266 | 20,3 % | 1 161 | 17,3 % | -8.29% |
Small Molecules
13,4
%
| 819 | 13,2 % | 901 | 13,4 % | +10.01% |
Cell & Gene
10,4
%
| 693 | 11,1 % | 696 | 10,4 % | +0.43% |
Corporate/Eliminations
3,6
%
| 171 | 2,7 % | 240 | 3,6 % | +40.35% |
Umsatz je Region
| CHF in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
|---|---|---|---|---|---|
United States
31,8
%
| 2 415 | 38,8 % | 2 136 | 31,8 % | -11.55% |
Switzerland
17,4
%
| 996 | 16,0 % | 1 168 | 17,4 % | +17.27% |
Japan
8,1
%
| 227 | 3,6 % | 544 | 8,1 % | +139.65% |
Ireland
5,5
%
| 343 | 5,5 % | 368 | 5,5 % | +7.29% |
Belgium
5,1
%
| 302 | 4,9 % | 341 | 5,1 % | +12.91% |
Denmark
4,8
%
| 158 | 2,5 % | 322 | 4,8 % | +103.80% |
Germany
4,5
%
| 224 | 3,6 % | 302 | 4,5 % | +34.82% |
Rest of Europe
2,9
%
| 207 | 3,3 % | 195 | 2,9 % | -5.80% |
China
2,6
%
| 161 | 2,6 % | 172 | 2,6 % | +6.83% |
United Kingdom
2,5
%
| 139 | 2,2 % | 171 | 2,5 % | +23.02% |
Singapore
2,0
%
| 113 | 1,8 % | 137 | 2,0 % | +21.24% |
Sweden
1,8
%
| 143 | 2,3 % | 123 | 1,8 % | -13.99% |
France
1,7
%
| 116 | 1,9 % | 111 | 1,7 % | -4.31% |
South Korea
1,4
%
| 141 | 2,3 % | 97 | 1,4 % | -31.21% |
Canada
1,3
%
| 63 | 1,0 % | 90 | 1,3 % | +42.86% |
Netherlands
1,3
%
| 132 | 2,1 % | 88 | 1,3 % | -33.33% |
Brazil
1,1
%
| 49 | 0,8 % | 71 | 1,1 % | +44.90% |
Italy
0,8
%
| 41 | 0,7 % | 52 | 0,8 % | +26.83% |
India
0,6
%
| 42 | 0,7 % | 42 | 0,6 % | -.--% |
Spain
0,6
%
| 41 | 0,7 % | 40 | 0,6 % | -2.44% |
Mexico
0,5
%
| 34 | 0,5 % | 33 | 0,5 % | -2.94% |
Rest of Asia
0,4
%
| 36 | 0,6 % | 29 | 0,4 % | -19.44% |
Rest of Latin America
0,4
%
| 38 | 0,6 % | 26 | 0,4 % | -31.58% |
Australia & New Zealand
0,2
%
| 21 | 0,3 % | 16 | 0,2 % | -23.81% |
Thailand
0,2
%
| 15 | 0,2 % | 15 | 0,2 % | -.--% |
Indonesia
0,2
%
| 16 | 0,3 % | 14 | 0,2 % | -12.50% |
Czech Republic
0,2
%
| 7 | 0,1 % | 11 | 0,2 % | +57.14% |
Other Countries
0,0
%
| 2 | 0,0 % | 2 | 0,0 % | -.--% |
Rest of North and Central America
0,0
%
| 1 | 0,0 % | 1 | 0,0 % | -.--% |
Manager
| Manager | Titel | Alter | Seit |
|---|---|---|---|
Albert Baehny
CEO | Chief Executive Officer | 72 | 25.04.17 |
Philippe Deecke
DFI | Director of Finance/CFO | 52 | 01.12.21 |
Maria Nunez
COO | Chief Operating Officer | 55 | 01.08.22 |
Lyle Wheeler
IRC | Investor Relations Contact | - | - |
Aufsichtsräte
| Aufsichtsräte | Titel | Alter | Seit |
|---|---|---|---|
Barbara Richmond
BRD | Director/Board Member | 63 | 16.04.14 |
| Director/Board Member | 66 | 16.04.14 | |
Marion Helmes
BRD | Director/Board Member | 58 | 05.05.22 |
Albert Baehny
CEO | Chief Executive Officer | 72 | 25.04.17 |
Christoph Mäder
BRD | Director/Board Member | 64 | 26.04.16 |
Roger Nitsch
BRD | Director/Board Member | 63 | 01.05.22 |
| Director/Board Member | 64 | 04.05.18 | |
| Director/Board Member | 52 | 04.05.18 |
Anteilsklasse
| Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
|---|---|---|---|---|---|
| Aktie A | 1 | 74 468 752 | 72 076 913 ( 96,79 %) | 2 352 163 ( 3,159 %) | 96,79 % |
Unternehmensbesitz
| Name | Aktien | % | Bewertung |
|---|---|---|---|
LONZA GROUP AG 3,16% | 2 352 163 | 3,16% | 1 268 183 853 $ |
Unternehmenskontakt
Konzerngesellschaften
| Name | Kategorie und Branche |
|---|---|
Lonza Biologics Plc
 Lonza Biologics Plc Miscellaneous Commercial ServicesCommercial Services Lonza Biologics Plc manufactures monoclonal antibodies, recombinant proteins and diagnostic monoclonal antibodies. The company was founded in 1897 and is headquartered in Slough, the United Kingdom. |
Miscellaneous Commercial Services
|
Lonza Swiss Finanz AG
 Lonza Swiss Finanz AG Finance/Rental/LeasingFinance Lonza Swiss Finanz AG engages in the provision of financing services within the companies of Lonza Group AG. It also invests in domestic and foreign industrial and commercial firms. The company was founded on December 23, 1974 and is headquartered in Basel, Switzerland. |
Finance/Rental/Leasing
|
Capsugel Plöermel SASU
 Capsugel Plöermel SASU BiotechnologyHealth Technology Capsugel Plöermel SASU designs and manufactures biopharmaceuticals. The company is headquartered in Ploermel, France. |
Biotechnology
|
Arch Chemicals Ltd.
 Arch Chemicals Ltd. Chemicals: SpecialtyProcess Industries Arch Chemicals Ltd. engages in the manufacture of inorganic basic chemicals. Its products are mainly used in the swimming pool for body treatment. The company was founded on February 24, 1978 and is headquartered in Castleford, the United Kingdom. |
Chemicals: Specialty
|
Capsugel France SAS
 Capsugel France SAS Apparel/Footwear RetailRetail Trade Capsugel France SAS manufactures & distributes clothes and clothing accessories. The company was founded in 1970 and is headquartered in Colmar, France. |
Apparel/Footwear Retail
|
Capsugel Belgium SA
 Capsugel Belgium SA Pharmaceuticals: MajorHealth Technology Capsugel Belgium NV provides dosage forms and solutions. The firm also sells equipment for filling empty and liquid capsules and equipment for sealing liquid capsules. The company was founded on October 1, 1961 and is headquartered in Bornem, Belgium. |
Pharmaceuticals: Major
|
Innovative Water Care Europe SAS
 Innovative Water Care Europe SAS Specialty StoresRetail Trade Innovative Water Care Europe SAS manufactures basic organic chemicals. The company was founded on September 17, 1982 and is headquartered in Amboise, France. |
Specialty Stores
|
Hickson Ltd.
 Hickson Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Lonza Group AG, Hickson Ltd. is a British company that provides business consulting services. The company is based in Castleford, UK. Hickson was founded in 1937. |
Miscellaneous Commercial Services
|
Arch UK Biocides Ltd.
 Arch UK Biocides Ltd. Household/Personal CareConsumer Non-Durables Part of Lonza Group AG, Arch UK Biocides Ltd. is a provider of integrated healthcare solutions to the pharmaceutical, biotech, and specialty ingredients markets. The company is based in Castleford, UK, and offers careers in various disciplines such as bioengineering and chemistry. Lonza optimizes scientific innovation and manufacturing technology to enable its customers to serve their patients and consumers. Lonza's quality management is committed to meeting all specifications and fulfilling customer needs and expectations. Founded in 2003, the British company's solutions aim to improve life quality by preventing illness, enabling healthier lifestyles, and supporting a safe environment. |
Household/Personal Care
|
Sektor
Umsatz nach Geschäftsbereich
Umsatz je Region
Verlauf des Gewinns je Aktie
| % 1. Jan. | Kap. | |
|---|---|---|
| +34.01% | 51.07 Mrd. | |
| -8.02% | 38.78 Mrd. | |
| -8.98% | 27.32 Mrd. | |
| +12.56% | 26.35 Mrd. | |
| -19.62% | 19.46 Mrd. | |
| +39.18% | 13.58 Mrd. | |
| +31.47% | 12.46 Mrd. | |
| -3.40% | 11.75 Mrd. | |
| -11.25% | 10.81 Mrd. |
- Börse
- Aktien
- 928619 Aktie
- 928619 Aktie
- Unternehmen Lonza Group AG
